@article{0013886541da47c195c29fb998578340,
title = "Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis",
keywords = "gemcitabine, GEMOX, nab-paclitaxel, oxaliplatin, pancreatic cancer, treatment costs, Gemcitabine, Humans, Pancreatic Neoplasms/pathology, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Oxaliplatin/therapeutic use, Fluorouracil/therapeutic use, Albumins, Paclitaxel, Retrospective Studies, Adenocarcinoma/pathology, Leucovorin/therapeutic use",
author = "Konstantin Schlick and Antonia Gantschnigg and Alexander Seymer and Florian Huemer and Richard Greil and Lukas Weiss",
note = "{\textcopyright} 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",
year = "2023",
month = aug,
doi = "10.1002/cam4.6334",
language = "English",
volume = "12",
pages = "16997--17004",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley & Sons Ltd.",
number = "16",
}